Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

A study was performed to assess the skin sensitisation potential of L-aspartic acid using the guineapig. The method followed was that described in: EEC Methods for the determination of toxicity, Annex of Directive 92169/EEC (OJ No: L383A, 29.12.92), Part B, Method B.6. Acute toxicity (skin sensitisation). Based on the results of a preliminary study and in compliance with the guideline, the following dose levels were selected: Intradermal injection: 0.01 % w/v in water for irrigation Topical application: 70 % w Iv in distilled water Challenge application: 70 and 35% w/v in distilled water Ten test and five control guinea-pigs were used in this study. In this study L-aspartic acid did not produce evidence of skin sensitisation (delayed contact hypersensitivity) in any of the test animals. L-aspartic acid does not require labelling with the risk phrase R43 "May cause sensitization by skin contact" in accordance with Council Directive 79/8311EEC Annex VI, Part II(D) as described in The Commission Directive 93/211EEC.


Migrated from Short description of key information:
A study was performed to assess the skin sensitisation potential of L-aspartic acid using the guineapig. The method followed was that described in: EEC Methods for the determination of toxicity, Annex of Directive 92169/EEC (OJ No: L383A, 29.12.92), Part B, Method B.6. Acute toxicity (skin sensitisation). Based on the results of a preliminary study and in compliance with the guideline, the following dose levels were selected: Intradermal injection: 0.01 % w/v in water for irrigation Topical application: 70 % w Iv in distilled water Challenge application: 70 and 35% w/v in distilled water Ten test and five control guinea-pigs were used in this study. In this study L-aspartic acid did not produce evidence of skin sensitisation (delayed contact hypersensitivity) in any of the test animals. L-aspartic acid does not require labelling with the risk phrase R43 "May cause sensitization by skin contact" in accordance with Council Directive 79/8311EEC Annex VI, Part II(D) as described in The Commission Directive 93/211EEC.

Justification for classification or non-classification

A study was performed to assess the skin sensitisation potential of L-aspartic acid using the guineapig. The method followed was that described in: EEC Methods for the determination of toxicity, Annex of Directive 92169/EEC (OJ No: L383A, 29.12.92), Part B, Method B.6. Acute toxicity (skin sensitisation). Based on the results of a preliminary study and in compliance with the guideline, the following dose levels were selected: Intradermal injection: 0.01 % w/v in water for irrigation Topical application: 70 % w Iv in distilled water Challenge application: 70 and 35% w/v in distilled water Ten test and five control guinea-pigs were used in this study. In this study L-aspartic acid did not produce evidence of skin sensitisation (delayed contact hypersensitivity) in any of the test animals. L-aspartic acid does not require labelling with the risk phrase R43 "May cause sensitization by skin contact" in accordance with Council Directive 79/8311EEC Annex VI, Part II(D) as described in The Commission Directive 93/211EEC.